<DOC>
	<DOCNO>NCT00209755</DOCNO>
	<brief_summary>Investigation usefullness therapeutical drug monitoring ribavirin dose adaptation combination therapy chronic hepatitis C patient . The correlation ribavirin plasma concentration level week 4 ( steady state ) early virological response ( HCV-RNA decay baseline week 12 ) test 40 patient approximately .</brief_summary>
	<brief_title>Plasma Ribavirin Assay During Combination Therapy Chronic Hepatitis C</brief_title>
	<detailed_description>1 . Background rational The serum concentrationS ribavirin commonly range 1 5 patient combination treatment « interferon+ribavirin » ( Larrat et al . 2003 ) . However , bioavailibility ribavirin consider current recommendation treatment . The aim study demonstrate adaptation « à la carte » ribavirin posology accord serum concentration could improve efficacy tolerance hepatitis C combination therapy . 2 . Study design This study prospective clinical pharmacology trial patient combination treatment chronic hepatitis C genotype 1 4 virus . The evaluation concern serum ribavirin concentration first three month treatment correlation evolution hemoglobin ( toxicity marker ) viral load ( efficacy marker ) . After 3 month study , adaptation posology base serum ribavirin level offer patient rest treatment period . A control ribavirin level one month dose adaptation perform . 3 . Study treatment This trial treatment evaluation . All patient receive treatment PegInterferon alfa-2a ribavirin accord register recommendation use . 4 . Target population The study population consist patient genotype 1 4 chronic hepatitis C combination therapy indicate . 5 . Main selection criterion Patients chronic hepatitis C relate genotype 1 4 virus combination therapy need eligible . Patients co-infection ( either VHB VIH ) concomitant treatment expect interact endpoint ( hemoglobin , viral load , serum ribavirin ) exclude . 6 . Judgement endpoint There intermediate endpoint : - blood hemoglobin concentration reduction 4 first week treatment marker toxicicty drug ( induction hemolytic anemiae ) - viral load reduction least 2 log 12 week treatment correlate sustained virologic response treatment - serum level ribavirin expect correlation two previous biological marker The primary judgement endpoint statistical correlation follow : - serum concentration ribavirine plateau pharmacokinetics ( J28 ( S4 ) ) - change hemoglobin concentration D0 D28 ( S4 ) - change hemoglobin concentration D0 D84 ( S12 ) 7 . Secondary endpoint The threshold efficacy toxicity ribavirin determine comparison responder/non responder patient ( predicted viral load change ) patient with/without toxicity . A correlation evolution two marker calculate .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patients chronic hepatitis C relate genotype 1 4 virus combination therapy need eligible . Patients coinfection ( either VHB VIH ) concomitant treatment expect interact endpoint ( hemoglobin , viral load , serum ribavirin ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>chronic hepatitis C</keyword>
</DOC>